Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat with R-DA-EPOCH in HIV-Related B-Cell NHL
NCT01193842Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2010
- Primary completion
- Nov 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vorinostat in B-cell non-Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Percentage of Participants With Complete Response at 6 months, Percentage of Participant Experiencing Adverse Events at 5 years and 1 more. Started Oct 2010; status: completed.
02
Drugs
vorinostat
03
Conditions
B-cell non-Hodgkin lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01193842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193842.